| Document |
Document Title |
|
WO/2022/068915A1 |
Provided are a 6-oxo-1,6-dihydropyridazin derivative, a preparation method therefor, and an application thereof in medicine. Specifically, the present invention relates to a 6-oxo-1,6-dihydropyridazin derivative as shown by general formu...
|
|
WO/2022/071334A1 |
The present invention provides a means for producing a parathyroid gland organoid. A culture method according to the present invention includes: a cell mass containing parathyroid gland cells at a content ratio of 50% or more and mesench...
|
|
WO/2022/067602A1 |
A crystal of a thyroid hormone ß receptor agonist, a preparation method therefor and use thereof. The crystal has substantially no hygroscopicity, and has a smaller crystal particle size and a larger drug specific surface area, so that ...
|
|
WO/2022/064035A1 |
The present invention relates to a sustained-release PTH compound for use in a method of improving and treating the physical and mental well-being of patients having hypoparathyroidism, wherein the sustained-release PTH compound releases...
|
|
WO/2022/057845A1 |
Provided are a compound serving as a thyroid hormone β receptor agonist and uses of the compound, also provided is a pharmaceutical composition comprising the compound. The compound or the pharmaceutical composition is applicable in pre...
|
|
WO/2022/058951A1 |
The present invention relates to luteinising hormone (LH) or to a molecule having LH-like activity or to a composition comprising it for use in inducing the activation, and/or the maturation of primordial and/or primary follicles in an i...
|
|
WO/2022/059700A1 |
The present invention provides a triazine compound salt that has an aldosterone synthase inhibitory effect and is useful as a medicine, in particular, an agent for preventing or treating primary aldosteronism and the like, a crystal, and...
|
|
WO/2022/057157A1 |
A traditional Chinese medicine composition for treating precocious puberty in children, and a preparation method therefor and the use thereof. The traditional Chinese medicine composition comprises the following raw materials in parts by...
|
|
WO/2022/052822A1 |
The present invention relates to a new crystal form of Resmetirom (referred to as "compound I") and a preparation method therefor, a pharmaceutical composition comprising the crystal from, and a use of the crystal form in preparing a THR...
|
|
WO/2022/052454A1 |
The use of an ester group-containing aromatic propionamide compound in the preparation of a medicine for treating dry eye syndrome.
|
|
WO/2022/055880A1 |
A spray-dried solid dispersion comprising: (a) 3 - [4 -(4 -amino -piperidin-I-y l)-3 -(3,5 -difluoro-phenyI)- quinolin-6 -yl] -2 -hydroxy-benzonitrile, or a pharmaceutically acceptable salt or solvate thereof; and (b) a pharmaceutically ...
|
|
WO/2022/047543A1 |
An intramedullary device for transplanting cells into a medullary cavity of a bone having an elongate shaft defining an internal lumen and a perforated region. The device further includes a semipermeable immuno-isolation housing within t...
|
|
WO/2022/047517A1 |
The present disclosure relates to methods for preparing derivatives of peptides and proteins, including preparing sialyl- glycosylated peptides and proteins, and to the resulting derivatives of peptides and proteins and their uses. The d...
|
|
WO/2022/049168A1 |
The present invention relates to the use of 17(S)-HDPA against metabolic syndrome related diseases including NAFLD/NASH.
|
|
WO/2022/050376A1 |
This target accumulation type complex has a structure in which a near-infrared photosensitive substance and a drug are linked to a carrier. By using the target accumulation type complex and a light delivery drug therapeutic method using ...
|
|
WO/2022/051330A1 |
Sustained-release abiraterone prodrug formulations, methods, and kits for parenteral administration to a subject having a sex hormone-dependent benign or malignant disorder such as prostate cancer, a syndrome due to androgen excess, and/...
|
|
WO/2022/041026A1 |
Provided herein are compounds and compositions useful for treating or preventing diseases or disorders that are modulated by thyroid hormone receptor agonists, such as non-alcoholic steatohepatitis (NASH) or non-alcoholic fatty liver dis...
|
|
WO/2022/046905A1 |
Provided are methods related to treating congenital adrenal hyperplasia in a subject in need thereof comprising administering to the subject a compound of Formula (I), or a pharmaceutically acceptable salt thereof.
|
|
WO/2022/046870A1 |
Disclosed are methods to prevent an occurrence of a high-grade serous ovarian cancer and/or breast cancer in a subject by administering a therapeutically effective amount of an antiprogestin to the subject.
|
|
WO/2022/037617A1 |
A compound represented by structural formula (I) and a pharmaceutically acceptable salt thereof and a pharmaceutical composition containing them, capable of being used as agonists of a thyroid hormone receptor -β, capable of being used ...
|
|
WO/2022/033303A1 |
The present invention relates to a benzylamine derivative, a preparation method therefor and use thereof, and in particular, to a benzylamine derivative as represented by general formula (I), or a pharmaceutically acceptable stereoisomer...
|
|
WO/2022/032484A1 |
Disclosed in the present invention are a pyridazine-3-formamide compound suitable for inhibiting or regulating the Janus kinase (JAK), in particular tyrosine kinase 2 (TYK2), and a preparation method therefor and the medical use thereof....
|
|
WO/2022/036181A1 |
Compositions and methods for converting at least one polyphenol to protocatechuic acid (PCA) using Bacillus subtilis (1579), or active variants thereof, are provided. Conversion of polyphenols, such as quercetin, to PCA can decrease infl...
|
|
WO/2022/031773A1 |
The present disclosure encompasses solid state forms of Fezolinetant, including salts and cocrystals of Fezolinetant, in embodiments crystalline polymorphs of Fezolinetant, processes for preparation thereof, and pharmaceutical compositio...
|
|
WO/2022/029101A1 |
The invention relates to certain 1,5-benzothiazepine and 1,2,5-benzothiadiazepine derivatives as defined herein. These compounds are bile acid modulators having apical sodium-dependent bile acid transporter (ASBT) and/or liver bile acid ...
|
|
WO/2022/028739A1 |
The present invention relates to a process for the preparation of viscous pharmaceutical formulations and to an apparatus for implementing the process. A gellable material is introduced into one chamber, a vehicle is introduced in the ot...
|
|
WO/2022/029499A1 |
Disclosed is a method for treating refractory ascites comprising administering ularitide to a patient in need thereof continuously for a time period between about 2 hours and about 168 hours. The method may further comprise bolus adminis...
|
|
WO/2022/031407A1 |
Disclosed herein are embodiments of a method comprising modifying GPR101 activity and/or growth hormone secretion using difeterol, vanoxeamine, and/or other compounds described herein. In particular embodiments, the compound embodiments ...
|
|
WO/2022/026415A1 |
A method of reducing or delaying the onset of fatty liver disease in a subject comprises enterally administering at least one human milk oligosaccharide (HMO) to a subject in need thereof in an amount effective to reduce hepatic lipid ac...
|
|
WO/2022/021638A1 |
A traditional Chinese medicinal composition for invigorating the spleen and removing turbidity, which consists of the following components in parts by weight: 15-25 parts of Pueraria lobata, 12-18 parts of red sage, 15-25 parts of Rhizom...
|
|
WO/2022/022476A1 |
The present invention relates to a crystal form and a pharmaceutically acceptable salt of a ketohexokinase (KHK) inhibitor, a preparation method therefor, and a pharmaceutical composition and an application thereof, and specifically rela...
|
|
WO/2022/020534A1 |
Compositions comprising miR-690 and methods of employing the compositions are provided.
|
|
WO/2022/017515A1 |
Provided in the present application are a diarylamine compound, a preparation method therefor and an application thereof. The compound has a structure represented by formula 1; R1 is selected from an alkyl group of C1-12, an alkoxy group...
|
|
WO/2022/019303A1 |
Provided is a pyrrole-imidazole polyamide that binds to the promoters of two or more genes and simultaneously controls transcription of the two or more genes. Also provided is a pharmaceutical composition comprising the pyrrole-imidazole...
|
|
WO/2022/009815A1 |
[Problem] The present invention addresses the problem of providing a compound that is suitable for use as a pharmaceutical bulk drug and that has high storage stability. [Solution] The present invention relates to a succinate of 1-{[(4aR...
|
|
WO/2022/011205A1 |
The present disclosure provides compounds represented by Formula I: A-L-B1 and the salts or solvates thereof, wherein A, L, and B1 are as defined in the specification. Compounds having Formula I are androgen receptor degraders useful for...
|
|
WO/2021/236779A9 |
Compounds and methods of modulating 15-PGDH activity, modulating tissue prostaglandin levels, treating disease, diseases disorders, or conditions in which it is desired to modulate 15-PGDH activity and/or prostaglandin levels include 15-...
|
|
WO/2022/004364A1 |
[Problem] To provide an agent capable of exhibiting an effect of adjusting autonomic dysfunction early at bedtime. [Solution] An effect of adjusting autonomic dysfunction early at bedtime is exhibited by an autonomic nerve-adjusting agen...
|
|
WO/2022/005891A1 |
Disclosed herein are compositions and in vitro and in vivo methods for reprogramming post-natal (adult and juvenile) tissue into insulinogenic cells. These compositions and methods are useful for a variety of purposes, including the deve...
|
|
WO/2022/004363A1 |
[Problem] The purpose of the present invention is to provide a drug capable of enhancing the female hormone-like action of equol. [Solution] According to this female hormone-like activity enhancer that comprises equol and carrot extract ...
|
|
WO/2022/002409A1 |
The present invention relates to Glucagon-Like Peptide-1 Receptor (GLP-1R) agonistic peptides with reduced GLP-1R agonistic activity, and fusion molecules comprising the same. The present invention also relates to nucleic acid molecules ...
|
|
WO/2022/005169A1 |
An injectable composition of the present invention has remarkably increased safety by forming, into a composition, a sorbitan unsaturated fatty acid ester having a polar head with two or more -OH (hydroxyl) groups, is in a liquid phase i...
|
|
WO/2021/261490A1 |
The present invention addresses the problem of acquiring a promoter that promotes the synthesis and secretion of testosterone without any side effects. The present inventors searched for materials having significantly high ability to pro...
|
|
WO/2021/260511A1 |
A multiphasic contraceptive and/or hormone replacement therapy regimen that provides for a low level of estrogen throughout the regimen. Also described is a kit that may be used for the multiphasic contraceptive and/or hormone replacemen...
|
|
WO/2021/262186A1 |
Described are assisted reproductive technology compositions and methods using highly purified menotropin (HP-hMG) to stimulate follicle development, particularly in women who have been diagnosed with oligoovulation and/or PCOS and who ar...
|
|
WO/2021/259143A1 |
The present application relates to the pharmaceutical use of a class of (E)-3-arylheterocyclyl prop-2-enoic acid derivatives. Such compounds are a class of new Nrf2 activators, which effectively activate the Nrf2 signaling pathway to pro...
|
|
WO/2021/261528A1 |
[Problem] To solve the problem of new COVID-19 pandemic by using Tinospora crispa or a plant analogous thereto. 1. Enhancement of recognition in countries other than the countries where Ayurveda is flourishing, for example, India, Pakist...
|
|
WO/2021/255560A1 |
Anatabine powder compositions include a sugar or adhesion reducing compound and are suitable for inhalation and methods of forming the same. Sugar and an anatabine compound may be spray dried to form a dry anatabine powder composition. T...
|
|
WO/2021/248408A1 |
An application of circular RNA to regulation and control of pancreatic islet β cell proliferation. The nucleotide sequence of the circular RNA is as shown in SEQ.ID.NO. 1 or SEQ.ID.NO. 2. Overexpression of the circular RNA can effective...
|
|
WO/2021/248256A1 |
Provided are a substituted pyrazole compound, and a preparation method therefor, the use thereof and a pharmaceutical composition thereof. The pyrazole compound is as represented by formula (I), is a STAT3 signaling pathway inhibitor, an...
|
